NIVO/IPI vs CTx in 1st line for MSI-H/dMMR mCRC #ASCO24 🔎CheckMate 8HW, 202 pts 👉PFS: nr vs 5.9mo, HR 0.21 👉Subsequent Tx: 12% vs 68%, in CTx arm: 67% ICI 👉mPFS2: nr vs 29.9, HR 0.27 👉24-mo PFS2: 83 vs 52% 🧐Impressive data -> SOC for MSI CRC ESMO - Eur. Oncology

📢 plenary #ASCO24 LAURA ph III RCT!! 👏🏽👏🏽 Suresh S. Ramalingam, MD, FASCO ➡️ n=216, adjuvant osimertinib after chemoRT for stage III #lungcancer ➡️ astonishing PFS HR 0.16💥 ➡️ immature survival outcomes, trend at HR 0.81 ➡️ ≥Grade 3 AEs in 35% vs 12% ➡️ crossover to osi allowed #lcsm #radonc

LAURA passes the "truck test" to a rousing ovation at #ASCO24 plenary session, with osimertinib given to patients with locally advanced unresectable stage III EGFRmut NSCLC with no progression following definitive chemoRT #lcsm nejm.org/doi/full/10.10…

#ASCO24 Plenary🔥 Ph III ADRIATIC trial of consolidation Durva +/-Treme post cCRT for LS SCLC: - benefit in mOS 55.9 v 33.4m (HR 0.73, p=0.01) & mPFS 16.6 v 9.2m - pneu 10.7% & RT pneu 22.4%* First advance in 30+yrs in LS SCLC @asco ESMO - Eur. Oncology IASLC OncoAlert David R. Spigel, MD, FASCO #LCSM

Another home-run for lung cancer at #ASCO24: the #ADRIATIC trial in limited-stage SCLC. #Durvalumab as consolidation treatment significantly prolongs PFS (HR 0.76, 16.6 vs 9.2 mo.) and OS (HR 0.73, 55.9 vs 33.4 mo.) compared to placebo! ASCO OncoAlert

Excellent summary!

Dose escalated RT also increasingly used after the OPERA data. Excellent CR rates with limited toxicity, in particular for "early tumors located at a terrible site". #radonc

Nice overview! Great authors, great articels! Clinical & Translational Radiation Oncology #asco24 #radonc

W O W

Durable complete responses to PD-1 blockade alone in mismatch repair deficient locally advanced rectal cancer #ASCO24 👉100% cCR, no relapse & no additional therapy 👉20 pts with sustained response of 12mo 👉ctDNA as an early marker of response 🧐Just amazing efficacy… ESMO - Eur. Oncology

The ULTRAS trial will shortly start recruiting patients with liver metastases led by Dr Ali Hosni from Princess Margaret Hospital, Toronto. The clinical hypothesis being investigated is whether a higher single dose of MRgRT improves local control in patients with liver mets

🚨🚨RTOG 0848🚨🚨 Anatomically resectable PDAC randomized postoperatively 1st randomization: Gemcitabine +/- erlotinib 🔥2nd Randomization🔥 +/- Chemoradiation, 50.4 Gy/28 fx + cape ✅⬆️ DFS w/ ☢️ ✅N0, ⬆️DFS and OS (5y 48% vs 29%) w/ ☢️ #ASCO24 NRG Oncology

🚨📢Happening now - HN oral abstracts #ASCO24‼️ PRACTICE CHANGING trial of hypoxia directed major radiation de-escalation as definitive treatment for HPV+OPC by Nancy Lee Memorial Sloan Kettering Radiation Oncology Memorial Sloan Kettering Cancer Center, showing that 30Gy+Chemo is sufficient for cure, with > 500 pts treated so far.

Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer Now fully published NEJM doi.org/10.1056/NEJMoa… 👉irTRAEs ≥ 3°: 4% 👉95% major pathological response 👉68% pathological complete response 👏just impressive... ESMO - Eur. Oncology

Hot off the press in ctRO by Rogers et al. 🔷 Preoperative Radiosurgery is highly feasible when scheduled the day before neurosurgery. 🔷 The surgical cavity local control rate was equivalent to that reported with postoperative fractionated SRS ctro.science/article/S2405-… #radonc

Team Tübingen at #DEGRO24.

Inspiring talk by Petra van Houdt nki about quantitative #MRI in #radiotherapy. Technical validation on the #MRL fruitful and ongoing and important open source initiatives out there. Thx for visiting Uniklinikum Tübingen! #medphys

Online First: Adaptive #radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell #lungcancer, according to [18F]FDG-PET uptake (RTEP7–IFCT-1402): a multicentre, randomised, controlled, phase 2 trial thelancet.com/journals/lanon…

A day in the life of an editor in chief... @ctro_journal #radonc

Archery - #1 sport NOT to do during your summer vacation if you are a #RadOnc and actually don’t want to think about random and systematic errors for 2 weeks… (but hey- not bad for a for attempt after a 15 year break??)